These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33631986)

  • 1. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
    Oruç Z; Kaplan MA; Karaağaç M; Özyurt N; Tatlı AM; Kaya AO; Menekşe S; Kut E; Koca S; Sever ÖN; Yasin İ; Ebinç S; Zeynelgil E; Sakin A; Turhal NS; Isikdogan A
    Future Oncol; 2021 May; 17(13):1611-1624. PubMed ID: 33631986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
    Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
    Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Aggarwal RR; Schweizer MT; Nanus DM; Pantuck AJ; Heath EI; Campeau E; Attwell S; Norek K; Snyder M; Bauman L; Lakhotia S; Feng FY; Small EJ; Abida W; Alumkal JJ
    Clin Cancer Res; 2020 Oct; 26(20):5338-5347. PubMed ID: 32694156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
    Izumi K; Mizokami A; Namiki M; Inoue S; Tanaka N; Yoshio Y; Ishibashi K; Kamiyama M; Kawai N; Enokida H; Shima T; Takahara S
    BMC Cancer; 2017 Oct; 17(1):677. PubMed ID: 29017493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L
    J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
    Yamamoto A; Kato M; Hattori K; Naito Y; Tochigi K; Sano T; Kawanishi H; Ishikawa T; Yuba T; Hattori R; Gotoh M; Tsuzuki T
    BJU Int; 2020 May; 125(5):702-708. PubMed ID: 31833179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
    Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
    Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES
    Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
    Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Bergman AM; van Moorselaar RJA; Coenen JLLM; van den Bergh ACM; Somford DM; Mehra N; van Oort IM; Aben KKH; Gerritsen WR; Uyl-de Groot CA
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):871-879. PubMed ID: 33746212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
    Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
    Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
    Demirci A; Bilir C; Gülbağcı B; Hacıbekiroğlu İ; Bayoğlu İV; Bilgetekin İ; Koca S; Çınkır HY; Akdeniz N; Gül D; Varım C; Demirci U; Öksüzoğlu B
    Sci Rep; 2021 Jul; 11(1):14131. PubMed ID: 34239026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
    George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS
    Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.